drugset / Trial / NCT03055494

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

NCT03055494

Phase 4 Completed 102 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.

Timeline

Start
2017-04-18
Primary completion
2018-04-25
Completion
2019-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 300 mg Subcutaneous

Indications